Inhaled nitric oxide therapy was not associated with postoperative acute kidney injury in patients undergoing lung transplantation

A retrospective pilot study

Hyun-Su Ri, MD,a Hyo Jung Son, MD,b Han Byeol Oh, MDc, Su-Young Kim, MD,a Ju Yeon Park, MDa, Ju Yeon Kim, MDb, Yoon Ji Choi, MD, PhD,a,b,c*

Abstract

Inhaled nitric oxide (iNO) therapy is commonly used in lung transplantation (LT) recipients during the perioperative periods. However, previous studies report that the use of iNO may increase the risk of renal dysfunction. Post-LT acute kidney injury (AKI) can lead to critical situations, including prolonged intensive care unit or hospital stays and increased morbidity and mortality. Accordingly, the aim of this study was to investigate the relationship between iNO therapy and incidence of post-LT AKI in LT recipients.

The medical data of 36 patients who underwent LT surgery from January 2012 to July 2017 in a single university hospital setting were retrospectively collected and analyzed. Patients were divided into 2 groups: iNO (n = 14) and control (n = 19). The demographic data, anesthetic methods, complications, and perioperative laboratory test values of each patient were assessed. Patients were categorized according to changes in plasma creatinine (Cr) concentration levels within 48 hours after LT using Acute Kidney Injury Network criteria.

There was no significant difference in the occurrence (P = .13) and severity (P = .9) of post-LT AKI between iNO and control groups. The mean serum Cr levels after surgery were 0.91 ± 0.44 and 0.81 ± 0.37 mg/dL in the iNO and control groups, respectively (P = .9). AKI plays a critical role in the prognosis of LT recipients. Our results revealed that iNO therapy was not associated with the incidence of post-LT AKI. Therefore, if iNO treatment is indicated, active use under close monitoring of renal function is recommended in LT-patients concerned about AKI after surgery.

Abbreviations: AKI = acute kidney injury, Cr = creatinine, LT = lung transplantation, NO = inhaled nitric oxide, NO2 = nitrogen dioxide, PH = pulmonary hypertension, RV = right ventricle.

Keywords: acute kidney injury, inhaled nitric oxide, lung transplantation

1. Introduction

Acute kidney injury (AKI) occurs in approximately 50% to 70% of patients after lung transplantation (LT),1,2 which is a crucial complication associated with short- and long-term prognosis of LT recipients. The majority of patients with AKI did not require dialysis but had significant association with chronic kidney disease and poor clinical outcome.3,4 Thus, additional efforts were needed to reduce the incidence of AKI in LT patients. Several factors that affect renal dysfunction in LT recipients include old age, medical treatments (corticosteroids, immunosuppressive treatment, diuretics, and nephrotoxic antibiotics), associated comorbidities (diabetes, hypertension, and pulmonary hypertension), reduction in effective blood volume during perioperative periods (intraoperative and postoperative bleeding), and low systemic vascular resistance owing to anesthetic drugs.5 Recently, there was a report that inhaled nitric oxide (iNO) therapy was related with the postoperative AKI.

The treatment of LT recipients with iNO during perioperative periods is one of the most important anesthetic strategies. The use of iNO has been shown to improve oxygenation by selectively reducing pulmonary vascular resistance and right ventricular filling pressure, and prevent reperfusion injury and graft dysfunction.6,7 Conventional, iNO has been used safely with clinically insignificant extra-pulmonary effects, including systemic vasodilation, methemoglobinemia, and decline of platelet function. Furthermore, it has been reported that iNO has an affirmative effect on renal, hepatic, and splanchnic perfusion.8 However, despite short-term improvement of oxygenation and right ventricular function, previous study showed that iNO therapy failed to alter clinically important patient outcomes such as the length of ICU stay and overall mortality.9 Ruan et al.10 reported that iNO therapy induced renal dysfunction and led to poor prognosis.

Post-LT AKI is a common complication and is associated with a worse outcome. Therefore, we sought to elucidate the
relationship between iNO therapy and the incidence of AKI in patients undergoing LT, and evaluate its impact on postoperative complications, and kidney function.

2. Methods

This retrospective study was approved by the institutional review board (No. 05-2017-145) of Pusan National University Yangsan Hospital, South Korea.

The medical records from our transplantation database of 36 patients who had received LT from January 2012 to July 2017 at Pusan National University Yangsan hospital were reviewed. Baseline demographics, comorbidities, and medications that may affect kidney function and preoperative laboratory findings were extracted from the computerized medical records. Exclusion criteria were as follows: repeated LT, history of end-stage renal disease with hemodialysis, showing unstable vital signs (mean blood pressure < 60 mm Hg despite vasopressor infusion) within 48 hours after surgery, and lack of available data.

The enrolled patients had undergone surgery under general anesthesia with target-controlled infusion (TCI). A commercial TCI pump (Orchestra Base Primea, Fresenius Vial, France) was used for the effect-site TCI of propofol (50 mL Fresofol 2% inj.; Fresenius Kabi, Austria) and remifentanil (1 mg Ultiva inj.; GlaxoSmithKline, Belgium), by using infusion models for propofol and remifentanil[11] that was maintained with a BIS value of 40 to 60. Cis-atracurium was used as a muscle relaxant.

Intraoperative monitoring of all patients involved electrocardiography, peripheral O2 saturation, end-tidal CO2 concentration, cerebral blood oxygenation, bispectral index, and invasive arterial monitoring via radial and femoral arteries. Subsequently, a pulmonary artery catheter (Swan-Ganz CCOmbo model: 744HF75, Edwards Lifesciences, Irvine, CA) was inserted via Advanced Venous Access Catheters (AVA High-Flow Devices, Edwards Lifesciences, Irvine, CA) and placed in the left internal jugular vein, and connected to a Vigilance monitoring system (Vigilance II monitor, Edwards Lifesciences, Irvine, CA), which allowed monitoring of stroke volume, stroke volume index, cardiac output, cardiac index, central venous oxygen saturation, and systemic vascular resistance index as parameters of fluid and circulatory management. During surgery, a crystalloid (Hartmann’s solution, normal saline, or plasma solution-A) was administered when either the mean arterial pressure < 60 mm Hg or the urine output < 0.5 mL/kg/h. Packed RBCs were considered only to maintain the hemoglobin concentration of 10 g/dl or a hematocrit concentration of 25% to 30% depending on the decision of the attending anesthesiologist. After using the kaolin-activated thromboelastography (TEG 5000 series; Haemoscope, Skokie, IL) before recipient’s lung was rewarmed, during anastomosis, and after anastomosis of donor’s lung to recipient was conducted, coagulation products were administered as needed. Pulmonary capillary wedge pressure was assessed to guide fluid management. Fluids were administered in order to maintain the pulmonary capillary wedge pressure between 6 and 15 mm Hg.

After the completion of surgery, patients were transferred to the intensive care unit (ICU) with intubation. Standardized postoperative care was provided to all patients with hemodynamic monitoring performed.

AKI in the postoperative period was diagnosed according to the Acute Kidney Injury Network (AKIN) criteria. Stage I was defined as an increase of serum creatinine (Cr) level from baseline of ≥ 0.3 mg/dl (normal reference range, 0.7–1.4 g/dl at our institution), or an increase from baseline range of 150% to −200%; stage II as an increase from baseline ranging from 200% to −300%; and stage III as an increase from baseline > 300%, or serum Cr level ≥ 4.0 mg/dl accompanied by an acute increase from baseline of ≥ 0.3 mg/dl, or requiring renal replacement therapy irrespective of other criteria.

2.1. Statistical analysis

Continuous variables were expressed as mean ± standard deviations and categorical variables as numbers and percentages. Baseline and intraoperative characteristics and variables for postoperative outcomes were compared using the t-test or the Mann–Whitney rank sum test for continuous variables, and the χ2 test or Fisher’s exact test for categorical variables.

All statistical analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC). A P-value < .05 was considered statistically significant. To confirm the adequacy of the number of subjects, the G*power software (version 3.1.9.3; Dusseldorf University, Dusseldorf, Germany) was used.[13]

3. Results

The flow diagram of patients through the study is shown in Figure 1. Of the 36 patients identified, we included only 33 patients who underwent LT. One patient underwent repeated surgery and 2 patients with missing data were excluded. Patients were divided into 2 groups: iNO (n = 14) and control (n = 19).

Patients’ characteristics including age, body mass index, cause of LT, preoperative status, and coexisting disease are shown in Table 1. There was no significant difference in patients’ characteristics. Preoperative laboratory data are shown in the following Table 2, which reveal no significant differences between the 2 groups including oxygen index and serum Cr.

Patients’ perioperative factors including duration of anesthesia, estimated blood loss, total volume of fluid intake, volume of transfusion per blood product, and urine output are listed in Table 3. There was also no significant difference.

The mean serum Cr levels after surgery were 0.91 ± 0.44 and 0.81 ± 0.37 mg/dl in the iNO and control groups, respectively. There was no significant difference between the 2 groups. AKI occurred in 57.1% (n = 8) of patients in the iNO group and 31.6% (n = 6) in the control group as demonstrated in Table 4, which did not demonstrate any significant difference between the 2 groups. There was no difference in the incidence of AKI from the whole cohort and the severity of renal dysfunction among patients with postoperative AKI between the 2 groups. Duration of ICU stay and total hospital stay showed no difference between the 2 groups. Postoperative complications also did not vary between the 2 groups (Table 5). The result of post-hoc power analysis was determined to be 0.88 based on an α-alpha value of 0.05, total sample size of 33 and an effect size of 0.55.

4. Discussion

In this retrospective review of LT recipients, iNO therapy was not associated with postoperative incidence or severity of AKI. In addition, iNO therapy did not affect postoperative complications, ICU stay, or total hospital stay.

LT is established for patients with a variety of end-stage lung diseases to improve quality of life and prolong life expectancy.[13,14] Although it is a lifesaving measure, LT is associated with well-known postoperative complications that contribute to
critical morbidity and mortality. \cite{13–15} Among them, postoperative AKI reduces survival rate of patient and graft. \cite{16,17} Moreover, prolonged AKI and newly developed chronic kidney disease are important risk factors for long-term morbidity after LT. \cite{18,19} In our study, the incidence of AKI after LT (81%) was higher than in other recent studies (50%–70%). \cite{1,2} However, there was no need for renal replacement therapy following LT in our study. Renal replacement therapy after LT was reported around 10% in previous studies. \cite{20,21} Several factors \cite{5,15,18} influenced the outcome of this study. Risk factors for the development of AKI after LT include sex, hypertension, diabetes mellitus, myocardial infarction, heart failure, and premorbid chronic renal disease, sepsis, and massive pulmonary embolism. In addition, the use of corticosteroids, immunosuppressive treatment, antibiotics, concurrent treatment with diuretics, angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers, and renal artery occlusion because of thrombus or embolism is associated with perioperative AKI. Low systemic vascular resistance owing to anesthetic drugs, and reduction in effective blood volume affect renal

### Table 1

**Characteristics of patients undergoing lung transplantation.**

|                          | Inhaled NO (n = 14) | Control (n = 19) | P value |
|--------------------------|---------------------|-----------------|---------|
| Age, years               | 56.0 (49.5–69.0)    | 58.0 (53.0–61.0) | .20     |
| Sex (F/M)                | 5 (35.7)/9 (47.3)   | 7 (36.8)/12 (63.2) | .62     |
| Height, cm               | 162.0 ± 10.08       | 163.5 ± 8.5      | .62     |
| Weight, kg               | 53.2 ± 10.4         | 57.4 ± 11.8      | .30     |
| Cause of lung transplantation                  | .66     |
| Idiopathic pulmonary fibrosis | 6 (42.9)   | 6 (31.6)    |         |
| Primary pulmonary hypertension      | 1 (7.1)    | 0           |         |
| Intestinal lung disease               | 7 (50.0)    | 13 (68.4)   |         |
| Pretransplant ECMO            | 9 (64.3)    | 15 (78.9)   | .25     |
| Pretransplant CRRT           | 6 (42.9)    | 5 (26.3)    | .56     |
| HTN                        | 3 (21.4)    | 3 (15.8)    | 1       |
| DM                         | 4 (28.6)    | 3 (15.8)    | 1       |
| HD                         | 0           | 2 (10.5)    | 1       |
| With diuretics             | 1 (7.1)     | 1 (5.3)     | .45     |
| With insulin               | 0           | 2 (10.5)    | 1       |

Values are expressed as mean ± SD, number (%).

CRRT = continuous renal replacement therapy, DM = diabetes mellitus, ECMO = extracorporeal membrane oxygenation, HTN = hypertension, HD = ischemic heart disease, NO = nitric oxide.

### Table 2

**Preoperative laboratory data in patients undergoing lung transplantation.**

|                          | Inhaled NO (n = 14) | Control (n = 19) | P value |
|--------------------------|---------------------|-----------------|---------|
| Oxygen index             | 29.8 ± 21.8         | 32.5 ± 21.7     | .39     |
| Hb, g/dL                 | 10.4 ± 2.5          | 10.6 ± 1.8      | .75     |
| PLT (× 10^3)/μL           | 182.0 ± 102.9       | 150.6 ± 71.0    | .31     |
| Protein, g/dL            | 5.8 ± 1.3           | 6.1 ± 1.3       | .64     |
| Albumin, mg/dL           | 3.1 ± 0.6           | 3.1 ± 0.6       | .81     |
| Creatinine, mg/dL        | 0.4 (0.4–0.7)       | 0.7 (0.4–0.9)   | .26     |
| Na, mEq/L                | 137.2 ± 4.6         | 135.4 ± 2.8     | .16     |
| K, mEq/L                 | 4.1 ± 0.6           | 4.1 ± 0.4       | .90     |

Values are expressed as mean ± SD or median (25th–75th percentile). Hb = hemoglobin, K = potassium, Na = sodium, NO = nitric oxide, PLT = platelet.


Table 3
Perioperative factors of patients undergoing lung transplantation.

|                        | Inhaled NO (n=14) | Control (n=19) | P value |
|------------------------|-------------------|----------------|---------|
| Anesthetic time, hours | 13.6±1.8          | 14.1±1.8       | .38     |
| VA ECMO time, hours    | 6.0 (5.0-6.0)     | 6.0 (5.0-7.4)  | .67     |
| EBL, L                 | 4.4 (2.0-9.2)     | 6.0 (2.0-8.8)  | .97     |
| Total fluid, L         | 8.9 (6.1-12.4)    | 8.1 (6.4-17.1) | .70     |
| pRBC, pints            | 15.0 (9-28)       | 15.0 (6-21)    | .97     |
| FFP, pints             | 13.5 (5-15)       | 9.0 (4-14)     | .97     |
| Cryo, pints            | 22.5 (15-30)      | 20.0 (18-30)   | .97     |
| PLT, pints             | 16.0 (5-32)       | 16.0 (9-24)    | .97     |
| Pheresis, pints        | 3.0 (2-9)         | 4.0 (3-5)      | .97     |
| Urine, L               | 1.8±1.0           | 2.3±0.8        | .17     |

Values are expressed as mean±SD or median (25th–75th percentile).

Table 4
Effect of NO inhalation on risk of AKI in patients undergoing lung transplantation.

|                        | Inhaled NO (n=14) | Control (n=19) | P value |
|------------------------|-------------------|----------------|---------|
| AKI                    | 8 (57.1)          | 6 (31.6)       | .14     |
| AKIN stage             |                   |                | .15     |
| 0                      | 6 (42.6)          | 13 (68.4)      | .14     |
| 1                      | 3 (21.4)          | 3 (15.8)       | .14     |
| 2                      | 4 (28.6)          | 2 (10.5)       | .14     |
| 3                      | 1 (7.1)           | 1 (5.3)        | .14     |

Values are expressed as number (%).

Table 5
Postoperative data of patients undergoing lung transplantation.

|                        | Inhaled NO (n=14) | Control (n=19) | P value |
|------------------------|-------------------|----------------|---------|
| Hb, g/dL               | 10.5±1.4          | 10.4±1.8       | .93     |
| PLT (x10^4)/mL         | 126.3±51.6        | 121.2±52.6     | .31     |
| Protein, g/dL          | 4.9 (4.3-5.1)     | 5.0 (4.3-5.4)  | .72     |
| Albumin, g/dL          | 2.9±0.4           | 2.7±0.6        | .30     |
| Creatinine, mg/dL      | 0.9±0.4           | 0.8±0.4        | .50     |
| Na, mEq/L              | 138.4±2.5         | 139.1±4.3      | .60     |
| K, mEq/L               | 4.3 (3.7-4.6)     | 4.4 (4.2-4.6)  | .35     |
| ICU stay, days         | 19.5 (15.0-27.0)  | 20.0 (11.0-26.0)| .70     |
| SOFA score             | 9.6±4.3           | 12.6±2.6       | .05     |
| APACHE II score        | 11.0±5.1          | 11.6±4.1       | .78     |
| Time from surgery to discharge, days | 50.1±39.4 | 64.7±61.0 | .31 |
| Postoperative complication |                 |                | .26     |
| Cardiac complication   | 2 (14.3)          | 2 (10.5)       | .35     |
| Respiratory complication | 1 (7.1)          | 2 (10.5)       | .35     |
| Neurologic complication | 0                | 0              | .35     |
| Acute rejection        | 0                 | 1 (5.3)        | .35     |

Values are expressed as mean±SD, number (%). Values are expressed as mean±SD or median (25th–75th percentile).

There are several limitations in our present study. First, this is a single center retrospective study with a small size, which appears to be insufficient to generalize the relationship between iNO and AKI. However, our findings showed no significant difference in the risk of post-LT AKI (P = 1.3) between iNO and control groups and the severity of renal dysfunction (P = .9) also showed no difference between the 2 groups. Furthermore, ICU stay time and from surgery to discharge also did not vary between the 2 groups.

In conclusion, we found that the use of iNO in LT patients at risk of AKI after surgery, active iNO treatment is recommended under close monitoring of renal function. In addition, as our study was limited by its retrospective design, we recommend further prospective randomized controlled multicenter studies as well as laboratory studies to investigate the association between iNO therapy and AKI.
Author contributions

Conceptualization: Hyun-Su Ri, Hyo Jung Son, Ju Yeon Kim, Yoon Ji Choi.
Data curation: Su-Young Kim, Yoon Ji Choi.
Formal analysis: Hyun-Su Ri, Yoon Ji Choi.
Funding acquisition: Yoon Ji Choi.
Investigation: Hyo Jung Son, Ju Yeon Park, Yoon Ji Choi.
Methodology: Hyun-Su Ri, Ju Yeon Park, Yoon Ji Choi.
Resources: Hyun-Su Ri, Han Byeol Oh, Yoon Ji Choi.
Supervision: Hyun-Su Ri, Yoon Ji Choi.
Validation: Hyun-Su Ri, Ju Yeon Park, Ju Yeon Kim, Yoon Ji Choi.
Visualization: Ju Yeon Kim, Yoon Ji Choi.
Writing – original draft: Hye Jung Son, Han Byeol Oh, Yoon Ji Choi.
Writing – review & editing: Hyun-Su Ri, Hye Jung Son, Su-Young Kim, Ju Yeon Kim, Yoon Ji Choi.

References

[1] Rocha PN, Rocha AT, Palmer SM, et al. Acute renal failure after lung transplantation: incidence, predictors and impact on perioperative morbidity and mortality. Am J Transplant 2005;5:1469–76.
[2] Grimm JC, Liu C, Kilic A, et al. A risk score to predict acute renal failure in adult patients after lung transplantation. Ann Thorac Surg 2015;99:251–7.
[3] Chawla LS, Amdur RL, Armodeo S, et al. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 2011;79:1361–9.
[4] Kline J, Rachou JS. Acute kidney injury and chronic kidney disease: it’s a two-way street. Ren Fail 2013;35:452–5.
[5] Carillo C, Pecoraro Y, Anile M, et al. Evaluation of renal function in patients undergoing lung transplantation. Transplant Proc 2017;49:699–701.
[6] Botha P, Jeyakanthan M, Rao JN, et al. Inhaled nitric oxide for modulation of schizophrenia-reperfusion injury in lung transplantation. J Heart Lung Transplant 2007;26:1199–205.
[7] Ardebali A, Laks H, Levine M, et al. A prospective trial of inhaled nitric oxide in clinical lung transplantation. Transplantation 2001;72:112–5.
[8] McMahon TJ, Doctor A. Extrapolmonary effects of inhaled nitric oxide: role of reversible S-nitrosylation of erythrocytic hemoglobin. Proc Am Thorac Soc 2006;3:153–60.
[9] Taylor RW, Zimmerman JL, Dellinger RP, et al. Inhaled nitric oxide in ASG. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA 2004;291:1603–9.
[10] Ruan SY, Huang TM, Wu HY, et al. Inhaled nitric oxide therapy and risk of renal dysfunction: a systematic review and meta-analysis of randomized trials. Crit Care 2015;19:137.
[11] Marsh B, White M, Morton N, et al. Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth 1991;67:41–8.
[12] Faul F, Erdfeilder E, Lang AG, et al. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:174–91.
[13] Fidalgo P, Ahmed M, Meyer SR, et al. Incidence and outcomes of acute kidney injury following orthotopic lung transplantation: a population-based cohort study. Nephrol Dial Transplant 2014;29:1702.
[14] Balcı MK, Vayvada M, Saliarç C, et al. Incidence of early acute kidney injury in lung transplant patients: a single-center experience. Transplant Proc 2017;49:593–8.
[15] Lyu DM, Zamora MR. Medical complications of lung transplantation. Proc Am Thorac Soc 2009;6:101–7.
[16] Wehbe E, Brock R, Budev M, et al. Short-term and long-term outcomes of acute kidney injury after lung transplantation. J Heart Lung Transplant 2012;31:244–51.
[17] Arnaoutakis GJ, George TJ, Robinson CW, et al. Severe acute kidney injury according to the RIFLE (risk, injury, failure, loss, end stage) criteria affects mortality in lung transplantation. J Heart Lung Transplant 2011;30:1161–8.
[18] Barracough K, Menahem SA, Bailey M, et al. Predictors of decline in renal function after lung transplantation. J Heart Lung Transplant 2006;25:1431–5.
[19] Hellemans ME, Bakker SJ, Postmus D, et al. Incidence of impaired renal function after lung transplantation. J Heart Lung Transplant 2012;31:238–43.
[20] George TJ, Arnaoutakis GJ, Beatty CA, et al. Acute kidney injury increases mortality after lung transplantation. Ann Thorac Surg 2012;94:183–92.
[21] Mason DP, Solovera-Rozas M, Feng J, et al. Dialysis after lung transplantation: prevalence, risk factors and outcome. J Heart Lung Transplant 2007;26:1155–62.
[22] Gozdzik W, Albert J, Harbut P, et al. Prolonged exposure to inhaled nitric oxide transiently modifies tubular function in healthy piglets and promotes tubular apoptosis. Acta Physiol (Oxf) 2009;195:495–502.
[23] Lukaszewicz AC, Mebazaa A, Callebert J, et al. Lack of alteration of endogenous nitric oxide pathway during prolonged nitric oxide inhalation in intensive care unit patients. Crit Care Med 2005;33:1008–14.
[24] Whitaker RM, Wills LP, Stallions LJ, et al. cGMP-selective phosphodiesterase inhibitors stimulate mitochondrial biogenesis and promote recovery from acute kidney injury. J Pharmacol Exper Ther 2013;347:626–34.
[25] Morsy MA, Ibrahim SA, Amin EF, et al. Sildenafil ameliorates gentamicin-induced nephrotoxicity in rats: role of iNOS and eNOS. J Toxicol 2014;2014:489382.
[26] Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:502.
[27] Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:502.
[28] Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:502.
[29] Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:502.
[30] Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:502.
[31] Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:502.
[32] Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:502.
[33] Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:502.
[34] Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:502.
[35] Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:502.
[36] Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:502.
[37] Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:502.
[38] Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:502.
[39] Weinberger B, Laskin DL, Heck DE, et al. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:502.